mepolizumab EGPA
Selected indexed studies
- Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. (N Engl J Med, 2024) [PMID:38393328]
- Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies. (Biomolecules, 2025) [PMID:40305320]
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. (N Engl J Med, 2017) [PMID:28514601]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. (2024) pubmed
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. (2017) pubmed
- Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies. (2025) pubmed
- Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study. (2025) pubmed
- Benralizumab noninferior to mepolizumab for EGPA. (2024) pubmed
- Long-Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis. (2025) pubmed
- Eosinophilic granulomatosis with polyangiitis: A review. (2023) pubmed
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. (2021) pubmed
- Update on eosinophilic granulomatosis with polyangiitis. (2019) pubmed
- Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. (2022) pubmed